AstraZeneca’s Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA’s Approval for Type-2 Diabetes in the US

 AstraZeneca’s Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA’s Approval for Type-2 Diabetes in the US

AstraZeneca’s Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA’s Approval for Type-2 Diabetes in the US

Shots:

  • The approval is based on two P-III studies assessing the combination of dapagliflozin (5mg, 10mg) ,saxagliptin (5mg) and metformin in patients with inadequately controlled Type-2 diabetes for 24wks.
  • The collective studies result demonstrated a reduction in HbA1c (average blood glucose levels) & increment in no. pf patients achieving HbA1c <7%
  • Qternmet XR (qd, PO) is a triple combination therapy consisting of dapagliflozin (sodium‑glucose cotransporter-2 (SGLT-2) inhibitor), saxagliptin (dipeptidyl peptidase‑4 (DPP‑4) inhibitor) & metformin hydrochloride , approved by FDA as an adjunct to diet and exercise for improving glycaemic control in adults with T-2D

Click here to read full press release/ article | Ref: AstraZeneca | Image: Simply Wall

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post